Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-4650 mRNA vaccine in metastatic melanoma, GI, and GU cancers
NCT03480152Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-4650 in melanoma, gastrointestinal cancer, genitourinary cancer, sponsored by National Cancer Institute. Started May 2018; status: terminated.
02
Drugs
mRNA-4650
03
Conditions
melanomagastrointestinal cancergenitourinary cancer
Beyond the preview
Go deeper on NCT03480152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480152.